Atlas Trials

Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

Clinical trial NCT01505634 · COMPLETED

Trial details

NCT number
NCT01505634
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Urinary Tract InfectionsPyelonephritis
Start date
2012-05-16
Primary completion
2015-07-28
Enrollment
302

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.